Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference: J.P. Morgan Healthcare Conference on Monday, January...
– Weekly Oral Helicase-Primase Inhibitor Programs' Early Data Potentially Supportive of First New Treatment for Recurrent Genital Herpes in 25 Years –
U.S. President Donald Trump announced Friday that nine drugmakers have agreed to lower the cost of their prescription drugs in the U.S. Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead...
Agreement addresses all requests by President Trump to reduce drug costs in the U.S., encourage global investment and protect American biopharma leadership ...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Keeley Wettan will be appointed Executive Vice President, General Counsel, Legal & Compliance effective immediately. She will join the company’s...
GILD, AMAT, and QCOM all stand out for their capacity to generate cash flow, which allows them to increase value to shareholders through dividends and buybacks.
– Investigational Treatment Regimen Could Expand Options for Virologically Suppressed Adults – – Positive Phase 3 Results from...
– Funding Empowers 53 Organizations to Enhance Education, Care and Support Services –